A British biopharmaceutical company will be trialling the use of CBD and other hemp-based products for treating opioid addiction, as well as other conditions.

Beckley Canopy Therapeutics has raised £7.4m to carry out research into the use of various extracts from the cannabis plant in order to develop medicines for people suffering cancer-related pain. In comparison, the US  National Center for Complementary and Integrative Health (NCCIH) has said it would spend up to $1.5m to fund research on minor cannabinoids and terpenes in the cannabis plant as it relates to responses to pain.

It is also hoped that any new treatments will be used to help reduce the use of opioid-based painkillers – a possible application of CBD in which there is already a great deal of interest.

Read full article
I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization